Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

528 - Is S-1/oxaliplatin with bevacizumab able to be an alternative chemotherapy against advanced/metastatic colorectal cancer?


19 Dec 2015


Poster presentation 1


Hiroshi Osawa


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


H. Osawa

Author affiliations

  • Oncology And Hematology, EDOGAWA HOSPITAL, 133-0052 - TOKYO/JP


Abstract 528


Chemotherapy with S-1 and oxaliplatin plus bevacizumab (B-SOX) is a new treatment for advanced or metastatic colorectal cancer. SOFT strial proved B-SOX which is non-inferior to mFOLFOX6 plus Bmab with respect to progression free survival as first-line chemotherapy for advanced or metastatic colorectal cancer. In contrast, there has been few reports on an efficacy and safety of combination chemotherapy as B-SOX in clinical situation. We aimed to recognize whether B-SOX is able to be an alternative first line chemotherapy against advanced or metastatic colorectal cancer in clinical situation or not.


This trial was retrospective trial. There were 60 advanced or metastatic colorectal patients enrolled. Treatment regimen; Bmab (7.5kg/kg) and L-OHP (130mg/m2) were administrated intravenously on day 1, while S-1 was administrated orally (80 mg/m2/day, twice a day) for 14-days followed by a 7-days break. Eligibility criteria. 1:histrogically proven colorectal adenocarcinoma, 2:ECOG PS score: 0–2, 3:presence of assessable lesions as confirmed by CT or MRI, 4:no previous chemotherapy or radiotherapy, 5:1) no age restrictions; 2) major organ function preserved; 3) no active multiple primary cancers seen; 4) recovered from postoperative complications; 5) no serious complications (intestinal obstruction, diarrhea, fever); 6) able to begin within 4–8 weeks after surgery; 7) provided written consent based on informed consent. Primary endpoints were best overall response and disease control rate, secoundary endpoints was safety.


Patients Characteristics No. of Patients(N = 60)
Gender male/Female 37/23
Age Median/Range 68/51-79 year
Primary Colon/Retal/Colorectal 31/22/7
Primary resection Yes/No 43/17
PS 0/1/2 21/29/10
Metastatic site Liver/Lung/LNs/Others 37/26/21/8
Best overall response CR/PR/SD/PD 0/50/8/2
Disease contorol rete CR + PR + SD 96.7%
PFS Median 10.6 months


In this study, SOX + BV chemotherapy showed tolerable toxicities and non-inferior response rate and diseases control to mFOLFOX6 + Bmab. And our result was similar PFS compare to SOFT trial. B-SOX chemotherapy is seemed to be valid choice for ambulatory chemotherapy.

Clinical trial identification

Investigator initiated trials


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings